• Takeda Pharmaceutical Co. Ltd., of Osaka, Japan, said favorable results from two Phase III studies, Gemini I and Gemini II, evaluating the humanized monoclonal antibody vedolizumab for moderately to severely active ulcerative colitis and Crohn's disease were published in the Aug. 22, 2013, issue of the New England Journal of Medicine.